Display options
Cite
Chirgwin ME, Dedloff MR, Holban AM, et al. Novel Therapeutic Strategies Applied to . Materials (Basel). 2019;12(24)doi: 10.3390/ma12244093.
Chirgwin, M. E., Dedloff, M. R., Holban, A. M., & Gestal, M. C. (2019). Novel Therapeutic Strategies Applied to . Materials (Basel, Switzerland), 12(24), . https://doi.org/10.3390/ma12244093
Chirgwin, Michael E, et al. "Novel Therapeutic Strategies Applied to ." Materials (Basel, Switzerland) vol. 12,24 (2019). doi: https://doi.org/10.3390/ma12244093
Chirgwin ME, Dedloff MR, Holban AM, Gestal MC. Novel Therapeutic Strategies Applied to . Materials (Basel). 2019 Dec 07;12(24). doi: 10.3390/ma12244093. PMID: 31817881; PMCID: PMC6947192.
Copy Download .nbib Format: NLM
Share it on

Materials (Basel). 2019 Dec 07;12(24). doi: 10.3390/ma12244093.

Novel Therapeutic Strategies Applied to .

Materials (Basel, Switzerland)

Michael E Chirgwin, Margaret R Dedloff, Alina Maria Holban, Monica C Gestal

Affiliations

  1. Department of Chemical Engineering, Clarkson University, Potsdam, NY 13699, USA.
  2. Department of Biology, Clarkson University, Potsdam, NY 13699, USA.
  3. Department of Microbiology, Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania.
  4. Research Institute of the University of Bucharest (ICUB), 050107 Bucharest, Romania.
  5. Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, University Politechnica of Bucharest, 1-7 Polizu Street, 011061 Bucharest, Romania.
  6. Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.

PMID: 31817881 PMCID: PMC6947192 DOI: 10.3390/ma12244093

Abstract

Cystic fibrosis (CF) is one of the most prevalent genetic diseases and a total of 1700 different genetic mutations can cause this condition. Patients that suffer this disease have a thickening of the mucus, creating an environment that promotes bacterial infections.

Keywords: Pseudomonas aeruginosa; bacteriophages; cystic fibrosis; liposomes; nanoparticles

References

  1. Antimicrob Agents Chemother. 2009 Sep;53(9):3847-54 - PubMed
  2. Pharmacol Res. 2001 May;43(5):497-502 - PubMed
  3. Respir Med. 2002 Dec;96(12):999-1005 - PubMed
  4. J Nanobiotechnology. 2010 Sep 24;8:22 - PubMed
  5. J Control Release. 2014 Oct 28;192:131-40 - PubMed
  6. Pharmacol Res. 2000 Dec;42(6):541-5 - PubMed
  7. Antimicrob Agents Chemother. 1996 Mar;40(3):665-9 - PubMed
  8. Antimicrob Agents Chemother. 2002 Aug;46(8):2575-81 - PubMed
  9. APMIS. 2017 Apr;125(4):304-319 - PubMed
  10. Antimicrob Agents Chemother. 1994 May;38(5):1090-5 - PubMed
  11. Pulm Pharmacol Ther. 2008 Dec;21(6):855-9 - PubMed
  12. Mol Pharm. 2013 Aug 5;10(8):2986-95 - PubMed
  13. Int J Pharm. 2013 Sep 15;454(1):233-40 - PubMed
  14. Eur J Pharm Biopharm. 2017 Aug;117:363-371 - PubMed
  15. J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):131-8 - PubMed
  16. J Control Release. 2012 Jan 10;157(1):149-59 - PubMed
  17. J Antimicrob Chemother. 2008 Apr;61(4):859-68 - PubMed
  18. Int J Nanomedicine. 2012;7:4053-63 - PubMed
  19. J Appl Microbiol. 2011 Jan;110(1):106-17 - PubMed
  20. Lancet. 2016 Nov 19;388(10059):2519-2531 - PubMed
  21. Antimicrob Agents Chemother. 2003 Apr;47(4):1301-7 - PubMed
  22. Biologicals. 2014 Jan;42(1):1-7 - PubMed
  23. J Appl Microbiol. 2010 Feb;108(2):695-702 - PubMed
  24. Int J Nanomedicine. 2019 Feb 25;14:1469-1487 - PubMed
  25. Int J Pharm. 2014 Dec 30;477(1-2):485-94 - PubMed
  26. Pharm Res. 2012 Dec;29(12):3335-46 - PubMed
  27. Biochem Pharmacol. 2002 Nov 1;64(9):1407-13 - PubMed
  28. Annu Rev Microbiol. 1993;47:139-66 - PubMed
  29. Colloids Surf B Biointerfaces. 2015 Nov 1;135:717-25 - PubMed
  30. J Aerosol Med Pulm Drug Deliv. 2015 Oct;28(5):353-60 - PubMed
  31. Biomed Res Int. 2013;2013:136859 - PubMed
  32. Antimicrob Agents Chemother. 2007 Jun;51(6):1934-8 - PubMed
  33. J Control Release. 2003 Oct 30;92(3):265-73 - PubMed
  34. Int J Pharm. 2012 Oct 15;436(1-2):771-7 - PubMed
  35. Materials (Basel). 2019 Jul 06;12(13):null - PubMed
  36. PLoS One. 2014 Dec 05;9(12):e114271 - PubMed
  37. Microb Drug Resist. 2006 Spring;12(1):1-6 - PubMed
  38. J Antimicrob Chemother. 1994 Dec;34(6):1001-13 - PubMed
  39. Perspect Biol Med. 2001 Winter;44(1):1-16 - PubMed
  40. Molecules. 2014 Apr 22;19(4):5013-27 - PubMed
  41. Future Microbiol. 2010 Nov;5(11):1663-74 - PubMed
  42. J Pharm Sci. 2011 Dec;100(12):5197-205 - PubMed
  43. Mol Pharm. 2019 Apr 1;16(4):1606-1619 - PubMed
  44. Front Microbiol. 2017 Oct 04;8:1917 - PubMed
  45. Int J Nanomedicine. 2010 Dec 16;6:35-43 - PubMed
  46. Pathogens. 2019 Apr 24;8(2):null - PubMed
  47. J Control Release. 2015 Jan 28;198:55-61 - PubMed
  48. Front Microbiol. 2018 Jul 05;9:1349 - PubMed

Publication Types